Vascular Biogenics (NASDAQ:VBLT) Stock Rating Reaffirmed by Chardan Capital

Vascular Biogenics (NASDAQ:VBLT)‘s stock had its “buy” rating restated by analysts at Chardan Capital in a report issued on Thursday, reports. They presently have a $3.25 price objective on the biopharmaceutical company’s stock. Chardan Capital’s target price points to a potential upside of 132.14% from the stock’s current price.

Other equities research analysts have also issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of Vascular Biogenics in a report on Friday, March 20th. Zacks Investment Research lowered shares of Vascular Biogenics from a “buy” rating to a “hold” rating in a report on Wednesday, March 4th. Roth Capital reaffirmed a “buy” rating on shares of Vascular Biogenics in a report on Thursday, January 2nd. Finally, ValuEngine raised shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $2.50.

Shares of VBLT traded up $0.25 during trading hours on Thursday, reaching $1.40. 102,177 shares of the company traded hands, compared to its average volume of 77,900. The stock has a market capitalization of $51.67 million, a P/E ratio of -2.40 and a beta of 1.08. The company has a quick ratio of 4.33, a current ratio of 4.33 and a debt-to-equity ratio of 0.06. Vascular Biogenics has a 12-month low of $0.90 and a 12-month high of $1.71. The business has a fifty day moving average price of $1.31 and a 200-day moving average price of $1.29.

Vascular Biogenics (NASDAQ:VBLT) last announced its quarterly earnings data on Thursday, March 19th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). The company had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.18 million. Vascular Biogenics had a negative net margin of 3,462.10% and a negative return on equity of 45.23%. As a group, research analysts predict that Vascular Biogenics will post -0.63 EPS for the current fiscal year.

An institutional investor recently raised its position in Vascular Biogenics stock. Renaissance Technologies LLC lifted its position in shares of Vascular Biogenics Ltd (NASDAQ:VBLT) by 81.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,615 shares of the biopharmaceutical company’s stock after acquiring an additional 16,003 shares during the quarter. Renaissance Technologies LLC owned 0.10% of Vascular Biogenics worth $43,000 as of its most recent SEC filing. Institutional investors own 4.22% of the company’s stock.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Further Reading: What is the Quick Ratio?

Analyst Recommendations for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with's FREE daily email newsletter.